KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Capital Expenditures (2016 - 2025)

Sarepta Therapeutics has reported Capital Expenditures over the past 15 years, most recently at $3.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 90.57% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $102.0 million, down 25.54%, while the annual FY2025 figure was $102.0 million, 25.54% down from the prior year.
  • Capital Expenditures for Q4 2025 was $3.6 million at Sarepta Therapeutics, down from $22.9 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $43.7 million in Q1 2025 and troughed at $2.2 million in Q4 2021.
  • A 5-year average of $19.2 million and a median of $18.5 million in 2023 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: crashed 92.29% in 2021 and later soared 261.02% in 2022.
  • Year by year, Capital Expenditures stood at $2.2 million in 2021, then soared by 261.02% to $8.0 million in 2022, then soared by 139.06% to $19.0 million in 2023, then soared by 100.02% to $38.1 million in 2024, then tumbled by 90.57% to $3.6 million in 2025.
  • Business Quant data shows Capital Expenditures for SRPT at $3.6 million in Q4 2025, $22.9 million in Q3 2025, and $31.8 million in Q2 2025.